Venn is poised for growth

The increase in biotechnoloogy research activity over the past few years offers opportunities for contract research organisation Venn Life Sciences.

The business

The boom in biotechnology shares in recent years has seen the sector raise a lot of money in order to develop new drugs. The total number of molecules in the global drug development pipeline has grown by an estimated 30 per cent to over 13,700 durning the past three years as a result. Likewise, the number of companies with an active R&D pipeline has more than doubled to around 3,700 in the decade.

To read more on this article : GCI (May 2016).

Venn Life Sciences Holdings plc published this content on 03 May 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 03 May 2016 14:13:02 UTC.

Original documenthttp://www.vennlifesciences.com/venn-poised-growth/

Public permalinkhttp://www.publicnow.com/view/72057B92217533048A080FD580ACE3D503B1C97A